Main description:

This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.

Contents:

1) Esketamine (Janssen Pharmaceutical Ltd., USA)Ella J. Daly (edaly2@its.jnj.com) or Jaskaran B. Singh (jsingh25@its.jnj.com)
2) (R)-Ketamine:Kenji Hashimoto (Chiba University, Japan) e-mail: hashimoto@faculty.chiba-u.jp
3) (2R,6R)-HNK (metabolite of R-ketamine):Todd D. Gould (University of Maryland, USA) (gouldlab@me.com) or Panos Zanos (panoszanos1986@gmail.com)
4) Lanicemine and BHV-5000 (low-trapping NMDAR antagonist)Biohaven Pharmaceutical (http://biohavenpharma.com/)
5) Rapastinel and Apimostinel: (Naurex OR Allergan)Joseph R. Moskal (Northwestern University, USA)( j-moskal@northwestern.edu)
6) AV-101 (L-4-chlorokynurenine: NMDAR glycine site antagonist):VistaGen Therapeutics (https://www.vistagen.com/)
7) TAK-653 (AMPAR potentiator):Haruhide Kimura (Takeda Pharmaceutical Co., Ltd, Japan) e-mail: haruhide.kimura@takeda.com
8) mGluR2/3 antagonists:Shigeyuki Chaki (Taisho Pharmaceutical Co, Ltd, Japan) e-mail: s-chaki@taisho.co.jp
9) SAGE-217 PAM at GABA-A:Sage Therapeutics, Inc. USA (https://www.sagerx.com/)
10) NAM at alpha-5 GABA-A:Scott M. Thompson (University of Maryland, USA) e-mail: sthompson@som.umaryland.edu
11) Scopolamine (muscarinic AChR antagonist):Ronald S. Duman (Yale University, USA) e-mail: ronald.duman@yale.edu
12) Sirukumab (IL-6 antibody)(Janssen Pharmaceutical Co, Ltd)Roger S. McIntyre (University of Toronto: roger.mcintyre@uhn.ca)
13) Seltorexant (orexin-2 receptor antagonist):Janssen Pharmaceutical Ltd. (Peter De Boer: pdeboer1@jts.jmj.com) ORMinera Neuroscience Inc. (Remy Luthringer) (http://www.minervaneurosciences.com/)
14) JNJ-55308942 (P2X7 antagonist)Anindya Bhattacharya (J&J, abhatta2@its.jnj.com)
15) Psilocybin (psychedelic drug)Compass Pathway (https://compasspathways.com/)